204 related articles for article (PubMed ID: 18753257)
1. Complement 5a receptor inhibition improves renal allograft survival.
Gueler F; Rong S; Gwinner W; Mengel M; Bröcker V; Schön S; Greten TF; Hawlisch H; Polakowski T; Schnatbaum K; Menne J; Haller H; Shushakova N
J Am Soc Nephrol; 2008 Dec; 19(12):2302-12. PubMed ID: 18753257
[TBL] [Abstract][Full Text] [Related]
2. Deficiency of C5aR prolongs renal allograft survival.
Li Q; Peng Q; Xing G; Li K; Wang N; Farrar CA; Meader L; Sacks SH; Zhou W
J Am Soc Nephrol; 2010 Aug; 21(8):1344-53. PubMed ID: 20651167
[TBL] [Abstract][Full Text] [Related]
3. Pharmacological targeting of C5a receptors during organ preservation improves kidney graft survival.
Lewis AG; Köhl G; Ma Q; Devarajan P; Köhl J
Clin Exp Immunol; 2008 Jul; 153(1):117-26. PubMed ID: 18505432
[TBL] [Abstract][Full Text] [Related]
4. Renal urokinase-type plasminogen activator (uPA) receptor but not uPA deficiency strongly attenuates ischemia reperfusion injury and acute kidney allograft rejection.
Gueler F; Rong S; Mengel M; Park JK; Kiyan J; Kirsch T; Dumler I; Haller H; Shushakova N
J Immunol; 2008 Jul; 181(2):1179-89. PubMed ID: 18606671
[TBL] [Abstract][Full Text] [Related]
5. Mesenchymal stem cells alleviate acute kidney injury by down-regulating C5a/C5aR pathway activation.
Tang M; Zhang K; Li Y; He QH; Li GQ; Zheng QY; Zhang KQ
Int Urol Nephrol; 2018 Aug; 50(8):1545-1553. PubMed ID: 29594894
[TBL] [Abstract][Full Text] [Related]
6. C5a promotes development of experimental lupus nephritis which can be blocked with a specific receptor antagonist.
Bao L; Osawe I; Puri T; Lambris JD; Haas M; Quigg RJ
Eur J Immunol; 2005 Aug; 35(8):2496-506. PubMed ID: 16052609
[TBL] [Abstract][Full Text] [Related]
7. C5a/C5aR pathway is essential for up-regulating SphK1 expression through p38-MAPK activation in acute liver failure.
Lei YC; Lu CL; Chen L; Ge K; Yang LL; Li W; Wu YH
World J Gastroenterol; 2016 Dec; 22(46):10148-10157. PubMed ID: 28028363
[TBL] [Abstract][Full Text] [Related]
8. Complement 5a receptor mediates angiotensin II-induced cardiac inflammation and remodeling.
Zhang C; Li Y; Wang C; Wu Y; Cui W; Miwa T; Sato S; Li H; Song WC; Du J
Arterioscler Thromb Vasc Biol; 2014 Jun; 34(6):1240-8. PubMed ID: 24743429
[TBL] [Abstract][Full Text] [Related]
9. C5aR, TNF-α, and FGL2 contribute to coagulation and complement activation in virus-induced fulminant hepatitis.
Liu J; Tan Y; Zhang J; Zou L; Deng G; Xu X; Wang F; Ma Z; Zhang J; Zhao T; Liu Y; Li Y; Zhu B; Guo B
J Hepatol; 2015 Feb; 62(2):354-62. PubMed ID: 25200905
[TBL] [Abstract][Full Text] [Related]
10. Targeted Complement Inhibition Protects Vascularized Composite Allografts From Acute Graft Injury and Prolongs Graft Survival When Combined With Subtherapeutic Cyclosporine A Therapy.
Zhu P; Bailey SR; Lei B; Paulos CM; Atkinson C; Tomlinson S
Transplantation; 2017 Apr; 101(4):e75-e85. PubMed ID: 28045880
[TBL] [Abstract][Full Text] [Related]
11. C5a receptor targeting in neointima formation after arterial injury in atherosclerosis-prone mice.
Shagdarsuren E; Bidzhekov K; Mause SF; Simsekyilmaz S; Polakowski T; Hawlisch H; Gessner JE; Zernecke A; Weber C
Circulation; 2010 Sep; 122(10):1026-36. PubMed ID: 20733098
[TBL] [Abstract][Full Text] [Related]
12. The receptor for activated complement factor 5 (C5aR) conveys myocardial ischemic damage by mediating neutrophil transmigration.
Mueller M; Herzog C; Larmann J; Schmitz M; Hilfiker-Kleiner D; Gessner JE; Theilmeier G
Immunobiology; 2013 Sep; 218(9):1131-8. PubMed ID: 23642836
[TBL] [Abstract][Full Text] [Related]
13. Complement C5a is detrimental to histological and functional locomotor recovery after spinal cord injury in mice.
Li L; Xiong ZY; Qian ZM; Zhao TZ; Feng H; Hu S; Hu R; Ke Y; Lin J
Neurobiol Dis; 2014 Jun; 66():74-82. PubMed ID: 24607885
[TBL] [Abstract][Full Text] [Related]
14. Depletion of cells of monocyte lineage prevents loss of renal microvasculature in murine kidney transplantation.
Qi F; Adair A; Ferenbach D; Vass DG; Mylonas KJ; Kipari T; Clay M; Kluth DC; Hughes J; Marson LP
Transplantation; 2008 Nov; 86(9):1267-74. PubMed ID: 19005409
[TBL] [Abstract][Full Text] [Related]
15. Treatment with anti-C5aR mAb leads to early-onset clinical and mechanistic effects in the murine delayed-type hypersensitivity arthritis model.
Atkinson SM; Nansen A; Usher PA; Sondergaard BC; Mackay CR; Friedrichsen B; Chang CC; Tang R; Skov S; Haase C; Hornum L
Autoimmunity; 2015; 48(7):460-70. PubMed ID: 25915570
[TBL] [Abstract][Full Text] [Related]
16. Effect of Timing and Complement Receptor Antagonism on Intragraft Recruitment and Protolerogenic Effects of Mesenchymal Stromal Cells in Murine Kidney Transplantation.
Casiraghi F; Todeschini M; Azzollini N; Cravedi P; Cassis P; Solini S; Fiori S; Rota C; Karachi A; Carrara C; Noris M; Perico N; Remuzzi G
Transplantation; 2019 Jun; 103(6):1121-1130. PubMed ID: 30801518
[TBL] [Abstract][Full Text] [Related]
17. Renal PKC-ε deficiency attenuates acute kidney injury and ischemic allograft injury via TNF-α-dependent inhibition of apoptosis and inflammation.
Rong S; Hueper K; Kirsch T; Greite R; Klemann C; Mengel M; Meier M; Menne J; Leitges M; Susnik N; Meier M; Haller H; Shushakova N; Gueler F
Am J Physiol Renal Physiol; 2014 Sep; 307(6):F718-26. PubMed ID: 25056349
[TBL] [Abstract][Full Text] [Related]
18. Novel insights in localization and expression levels of C5aR and C5L2 under native and post-transplant conditions in the kidney.
van Werkhoven MB; Damman J; Daha MR; Krikke C; van Goor H; van Son WJ; Hillebrands JL; van Dijk MC; Seelen MA
Mol Immunol; 2013 Mar; 53(3):237-45. PubMed ID: 22960554
[TBL] [Abstract][Full Text] [Related]
19. Enhancement of human cancer cell motility and invasiveness by anaphylatoxin C5a via aberrantly expressed C5a receptor (CD88).
Nitta H; Wada Y; Kawano Y; Murakami Y; Irie A; Taniguchi K; Kikuchi K; Yamada G; Suzuki K; Honda J; Wilson-Morifuji M; Araki N; Eto M; Baba H; Imamura T
Clin Cancer Res; 2013 Apr; 19(8):2004-13. PubMed ID: 23287562
[TBL] [Abstract][Full Text] [Related]
20. Leucocyte expression of complement C5a receptors exacerbates infarct size after myocardial reperfusion injury.
De Hoog VC; Timmers L; Van Duijvenvoorde A; De Jager SC; Van Middelaar BJ; Smeets MB; Woodruff TM; Doevendans PA; Pasterkamp G; Hack CE; De Kleijn DP
Cardiovasc Res; 2014 Sep; 103(4):521-9. PubMed ID: 24935433
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
